New Lung Cancer Treatments Attributed to Recent Decline in Mortality Rates

August 13, 2020 by No Comments

Good news! Deaths from the most common form of lung cancer, non small cell (NSCLC), have decreased significantly in the United States over the last couple of years. The study was performed by researchers at the National Cancer Institute, and have determined that there is a direct correlation between recently approved targeted therapies and the drop in mortalities.

The study found that although incidence of NSCLC was decreasing, the death rate of the diagnosed was decreasing at a more significant rate, thus pointing to effective treatment options. Among men, from 2006-2013, the mortality rate decreased 3.2% annually. From 2013-2016 it decreased an even greater 6.3% annually.

The researchers posit that the accelerating decline in 2013 aligns with a new practice to test patients for genetic alterations that can be targeted by newly approved drugs. There are additional therapies that have been increasingly used since 2016 that will not show up in the study. This leads the researchers to believe that the trend will continue and mortality rates will further decline as we implement new methods of detection and treatment.

Source: NIH Story